TY - JOUR
T1 - Proceedings of the Ninth HDL (High-Density Lipoprotein) Workshop
T2 - Focus on Cardiovascular Disease
AU - Rodriguez, Annabelle
AU - Trigatti, Bernardo L.
AU - Mineo, Chieko
AU - Knaack, Darcy
AU - Wilkins, John T.
AU - Sahoo, Daisy
AU - Asztalos, Bela F.
AU - Mora, Samia
AU - Cuchel, Marina
AU - Pownall, Henry J.
AU - Rosales, Corina
AU - Bernatchez, Pascal
AU - Ribeiro Martins Da Silva, Amanda
AU - Getz, Godfrey S.
AU - Barber, Jacob L.
AU - Shearer, Gregory C.
AU - Zivkovic, Angela M.
AU - Tietge, Uwe J.F.
AU - Sacks, Frank M.
AU - Connelly, Margery A.
AU - Oda, Michael N.
AU - Davidson, W. Sean
AU - Sorci-Thomas, Mary G.
AU - Vaisar, Tomas
AU - Ruotolo, Giacomo
AU - Vickers, Kasey C.
AU - Martel, Catherine
N1 - Funding Information:
In this year’s program, the HDL Workshop took place in Boston, MA, over a 2-day period. It included oral presentations from invited established investigators as well as short talks from trainees. A new feature was a poster presentation session. The highlight of the event was the annual Jack Oram Research Award, honoring the late Dr Jack Oram and generously funded by the Dyslipidemia Foundation of Boston. This year’s award was presented to the distinguished professor emeritus Dr G.S. Getz from the University of Chicago.
Funding Information:
Dr Rodriguez is the founder of Lipid Genomics and declares inventorship rights to issued patents related to HDL biology. B.L. Trigatti declares inventorship rights to issued patents related to Scarb1−/− mice. J.T. Wilkins declares having served as a consultant for NGM Bio. S. Mora declares having received research support from Atherotech Diagnostics and serving as a consultant to Quest Diagnostics and Pfizer. M. Cuchel declares receiving support for clinical trials unrelated to HDL from Akcea Therapeutics, Regeneron Pharmaceuticals, and Regenxbio. C.Rosales was supported by NIH HL129767. G.C. Shearer declares receiving speakership and advisory panel honoraria from Amarin Pharmaceuticals. F. Sacks declares being a consultant for Pfizer and AstraZeneca. M.A. Connelly is an employee of LabCorp, which offers lipoprotein profiling services via nuclear magnetic resonance spectroscopy (NMR). M.N. Oda is the founder of DRx BioLogics, Inc. T. Vaisar is a consultant for MedImmune/AstraZeneca. Dr Giacomo Ruotolo is an employee of Eli Lilly and Company. The other authors report no conflicts.
Funding Information:
Dr Rodriguez has been supported by a National Institutes of Health (NIH) HL131862 grant and an endowment from the Linda and David Roth Chair of Cardiovascular Research. B.L. Trigatti has received funding support from the Ca- nadian Institutes of Health Research (MOP74753, PJT-156437, and PJT-162272) and the Heart and Stroke Foundation of Canada (G-16-00014064 and G-19-0026275). C. Mineo was supported by NIH HL126795. D. Knaack was supported by the Cardiovascular Center and the Advancing Healthier Wisconsin Endowment. J.T. Wilkins received grant support from the NIH/NHLBI K23HL133601-04. D. Sahoo was supported by NIH HL58012. B. Asztalos was supported by NIH HL117933. S. Mora has received support from the National Institutes of Health (HL134811, HL117861, HL136852, and DK112940). M. Cuchel has received support from the NIH HL059407. H.J. Pownall was supported by NIH HL129767. C. Rosales was supported by NIH HL129767. P. Bernatchez was supported by the Canadian Institutes of Health Research and the Jain Foundation. G.S. Getz was supported by HL131028. J.L. Barber was supported by multiple grants from the NIH to Dr Sarzynski: NIH/NIGMS P20 GM103499 and NIH/ NHLBI R01HL146462. Rohatgi: NIH/NHLBI R01HL136724, NIH/NHLBI K08HL118131, and American Heart Association 15CVGPSD27030013. The HERITAGE Family Study: NIH HL45670. Dr Gregory C. Shearer was supported by HL130099 and institutional funds. A.M. Zivkovic was supported by USDA National Institute of Food and Agriculture, Hatch project CA-D-NUT-2242-H and NIH grant R01 AG062240. W.S. Davidson was supported by NIH P01HL128203 grant. M.G. Sorci-Thomas was supported by NIH HL127649 and HL38907 grants. T. Vaisar was supported by NIH grants P30DK017047, P01HL092969, P01HL128203, and R01HL144558. K.C. Vickers was supported by NIH Awards HL128996, HL127173, and HL116263. C. Martel as supported by grants from the Canadian Institutes of Health Research (363262), the Natural Sciences and Engineering Research Council of Canada (RGPIN-2016-05331), the Canadian Foundation for Innovation (35289, a Fond de recherche du Quebec - Santé - New investigator award (Research Scholars - Junior 1) and a Canada Research Chair 2 in Lymphatics and Cardiovascular Medicine.
Publisher Copyright:
© 2019 American Heart Association, Inc.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - The HDL (high-density lipoprotein) Workshop was established in 2009 as a forum for candid discussions among academic basic scientists, clinical investigators, and industry researchers about the role of HDL in cardiovascular disease. This ninth HDL Workshop was held on May 16 to 17, 2019 in Boston, MA, and included outstanding oral presentations from established and emerging investigators. The Workshop featured 5 sessions with topics that tackled the role of HDL in the vasculature, its structural complexity, its role in health and disease states, and its interaction with the intestinal microbiome. The highlight of the program was awarding the Jack Oram Award to the distinguished professor emeritus G.S. Getz University of Chicago. The tenth HDL Workshop will be held on May 2020 in Chicago and will continue the focus on intellectually stimulating presentations by established and emerging investigators on novel roles of HDL in cardiovascular and noncardiovascular health and disease states.
AB - The HDL (high-density lipoprotein) Workshop was established in 2009 as a forum for candid discussions among academic basic scientists, clinical investigators, and industry researchers about the role of HDL in cardiovascular disease. This ninth HDL Workshop was held on May 16 to 17, 2019 in Boston, MA, and included outstanding oral presentations from established and emerging investigators. The Workshop featured 5 sessions with topics that tackled the role of HDL in the vasculature, its structural complexity, its role in health and disease states, and its interaction with the intestinal microbiome. The highlight of the program was awarding the Jack Oram Award to the distinguished professor emeritus G.S. Getz University of Chicago. The tenth HDL Workshop will be held on May 2020 in Chicago and will continue the focus on intellectually stimulating presentations by established and emerging investigators on novel roles of HDL in cardiovascular and noncardiovascular health and disease states.
UR - http://www.scopus.com/inward/record.url?scp=85075813183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075813183&partnerID=8YFLogxK
U2 - 10.1161/ATVBAHA.119.313340
DO - 10.1161/ATVBAHA.119.313340
M3 - Review article
C2 - 31597448
AN - SCOPUS:85075813183
SN - 1079-5642
VL - 39
SP - 2457
EP - 2467
JO - Arteriosclerosis, thrombosis, and vascular biology
JF - Arteriosclerosis, thrombosis, and vascular biology
IS - 12
ER -
